期刊文献+

辛伐他汀对冠心病PCI术后患者颈动脉内中膜的影响

下载PDF
导出
摘要 目的:观察辛伐他汀治疗对PCI术后患者颈动脉内中膜的影响。方法:回顾分析103例PCI术后患者,观察其服用辛伐他汀20mg/日,1年前后的颈动脉内中膜厚度(IMT)。根据患者治疗前后LDL水平分为3个亚组,A组治疗前后LDL均低于80mg/dl;B组治疗前后LDL水平均高于80mg/dl;C组治疗前LDL水平高于80mg/dl,治疗后LDL水平低于80mg/dl。结果:给予辛伐他汀治疗1年后,患者的TCH、LDL水平有明显下降。同时apoA水平升高,颈动脉内中膜厚度下降,并有统计学差异,通过亚组分析发现:A组中,伴随LDL水平的降低,内中膜有下降趋势,但未达到统计学意义。B组中,治疗前后LDL和内中膜水平均无明显改变。C组中,LDL水平和内中膜厚度的降低有统计学意义。结论:冠心病患者经长期的他汀药物治疗,可以使颈动脉内中膜厚度减少,对于冠心痛患者降脂幅度达标(30%~40%)可能比降脂达标者(LDL<80mg/dl),更能有效降低颈动脉内中膜厚度,改善动脉硬化程度。
作者 许宏俊
出处 《中国社区医师(医学专业)》 2012年第18期205-206,共2页
  • 相关文献

参考文献7

  • 1高润霖.他汀类药物在急性冠状动脉综合征的应用[J].中华心血管病杂志,2003,31(8):635-636. 被引量:150
  • 2Yamada T,Azuma A,Sasaki S,et al.Randomized evaluation of atorvastatin in patients with coronary heart disease a serial intravascular ultrasound study[J].Cire,2007,71(12):1845-1850.
  • 3Clearfield M.Rosuvastatin and carotid intima-media thickness:the METEOR trial[J].Curt Atheroscler Rep,2008,10(1):6-7.
  • 4Lee Y H,Cui L H,Shin M H,et al.Associations between carotid intima-media thickness,plaque and cardiovascular risk factors[J].Prey Med Pub Health,2006,39(6):477.
  • 5Crouse J R,Byington R P,Bond M G,et al.Pravastatin.1ip ids,and atherosclerosis in the carotid arteries(PLAC-H)[J].AmJ Cardiol,2005,75(7):455.
  • 6Corti R,Fayad z A,Fuster V,et al.Effects of lipidlowering by simvastatin on human atherosclerotic lesions[J].Circulation,2004,104(3):249-252.
  • 7秦晋梅,李建军.他汀类药物的抗炎作用[J].中国动脉硬化杂志,2004,12(3):363-366. 被引量:42

二级参考文献44

  • 1Simes J, Furberg CD, Braunwald E, Davis BR, Ford I, Tonkin A, et al.Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels.The Prospective Pravastatin Pooling project.Eur Heart J, 2002, 23 (3):207-215
  • 2Scandinavian Simvastatin Survival Study Group.Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease:the Scandinavian Simvastatin Survival Study (4S).Lancet, 1994, 344:1 383-389
  • 3Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al.Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels:results of AFCAPS/TexCAPS.Air Force/Texas Coronary Atherosclerosis Prevention Study.J Am Med Assoc, 1998, 279 (20):1 615-622
  • 4Plutzky J, Ridker PM.Statins for Stroke:The Second Story? Circulation, 2002, 103 (3):348-350
  • 5Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, et al.Effect of pravastatin on outcomes after cardiac transplantation.N Engl J Med, 1995, 333 (10):621-627
  • 6Wenke K, Meiser B, Thiery J, Nagel D, Scheidt WV, Steinbeck G, et al.Simvastatin reduces graft vessel disease and mortality after heart transplantation.Circulation, 1997, 96 (5):1 398-402
  • 7Strandberg TE, Vanhanen H, Tikkanen MJ.Effect of statins on C-reactive protein with coronary artery disease.Lancet, 1999, 353(9147):118-119
  • 8Rider PM, Rifai N, Pfeffer M, Sacks F, Braunwald E.For the cholesterol and recurrent event (CARE) investigators.Long-term effects of pravastatin on plasma concentration of C-reactive protein.Circulation, 1999, 100 (3):230-235
  • 9Albert MA, Staggers J, Chew P, Rider PM.The pravastatin inflammation CRP evaluation (PRINCE):rationale and design.Am Heart J, 2001, 141 (6):893-898
  • 10Albert MA, Danielson E, Rifai N, Ridker PM.Effect of statin therapy on C-reactive protein levels - The Pravastatin Inflammation / CRP Evaluation (PRINCE):A randomize trial and cohort study.J Am Med Assoc, 2001, 286 (1):64-70

共引文献189

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部